SCHEMBL2238552

SCHEMBL2238552

CCOC(=O)[C@@H](N)CSCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.60
NPC1 O15118 2/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
IDO1 P14902 1/20 0.47
ELANE P08246 1/20 0.46
MMP8 P22894 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
POLB P06746 1/20 0.44
CYP2C9 P11712 1/20 0.44
PIN1 Q13526 1/20 0.43
CYP2C19 P33261 1/20 0.42
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
ACE P12821 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7323491 1.00 METAP2 (0.60) METAP2NPC1RAB9ASMN1; SMN2IDO1
Hydrochloric Acid SCHEMBL7323488 0.98 METAP2 (0.59) METAP2NPC1RAB9ASMN1; SMN2IDO1
Hydrochloric Acid SCHEMBL3366424 0.98 METAP2 (0.59) METAP2NPC1RAB9ASMN1; SMN2IDO1
SCHEMBL10519231 0.88 ALDH1A1 (0.49) METAP2NPC1RAB9ASMN1; SMN2IDO1
SCHEMBL7317999 0.87 METAP2 (0.47) METAP2NPC1RAB9ASMN1; SMN2MMP8
SCHEMBL8413073 0.86 IDO1 (0.48) METAP2IDO1CYP2C19PPARGPPARA
SCHEMBL1839764 0.86 METAP2 (0.52) METAP2IDO1CYP2C19PPARGPPARA
SCHEMBL2553802 0.86 METAP2 (0.52) METAP2IDO1CYP2C19PPARGPPARA
SCHEMBL4141148 0.86 METAP2 (0.52) METAP2IDO1CYP2C19PPARGPPARA
SCHEMBL28431790 0.86 METAP2 (0.47) METAP2IDO1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200231532-A1 Supported Metal Catalysts JOHNSON MATTHEY PLC (GB) 2020-07-23 US claimed
US-20180099923-A1 Supported Metal Catalysts JOHNSON MATTHEY PLC (GB) 2018-04-12 US claimed
EP-2536500-B1 SUPPORTED METAL CATALYSTS JOHNSON MATTHEY PLC (GB) 2016-12-07 EP claimed
US-20130072722-A1 SUPPORTED METAL CATALYSTS JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2013-03-21 US claimed
EP-2536500-A1 SUPPORTED METAL CATALYSTS Johnson Matthey PLC (GB) 2012-12-26 EP claimed
WO-2011101679-A1 SUPPORTED METAL CATALYSTS JOHNSON MATTHEY PLC (GB) 2011-08-25 WO claimed
EP-3015488-B1 PRODUCTION METHOD FOR POLYAMINO ACID TAKEDA PHARMACEUTICALS CO (JP) 2024-03-06 EP disclosed
US-20200231532-A1 Supported Metal Catalysts JOHNSON MATTHEY PLC (GB) 2020-07-23 US disclosed
US-10336864-B2 Production method for poly(amino acid) TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-07-02 US disclosed
US-20180099923-A1 Supported Metal Catalysts JOHNSON MATTHEY PLC (GB) 2018-04-12 US disclosed
US-20180044472-A1 PRODUCTION METHOD FOR POLY(AMINO ACID) TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-02-15 US disclosed
US-9815938-B2 Production method for poly(amino acid) TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-11-14 US disclosed
EP-2536500-B1 SUPPORTED METAL CATALYSTS JOHNSON MATTHEY PLC (GB) 2016-12-07 EP disclosed
EP-0050800-B1 CARBOXYALKYL DIPEPTIDES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SCHERING CORPORATION (US) 1986-06-18 EP disclosed
US-4575503-A ANGIOTENSIN CONVERTING ENZYME INHIBITOR, HYPOTENSIVE CIBA-GEIGY CORPORATION (US) 1986-03-11 US disclosed
EP-0088350-B1 CARBOXYALKYL DIPEPTIDES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SCHERING CORPORATION (US) 1985-02-20 EP disclosed
EP-0119954-A2 3-Amino-1-benzazepin-2-one-1-alcanoic acids, process for their preparation, their pharmaceutical preparation as well as their therapeutic use CIBA-GEIGY AG (CH) 1984-09-26 EP disclosed
US-4431644-A CARDIOVASCULAR DISORDERS; DIURETICS SCHERING CORPORATION (US) 1984-02-14 US disclosed
EP-0088350-A1 Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them SCHERING CORPORATION (US) 1983-09-14 EP disclosed
EP-0050800-A1 Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them SCHERING CORPORATION (US) 1982-05-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072722-A1 SUPPORTED METAL CATALYSTS SOD1, HNMT, SOD3 METAP2 405/4885NPC1 3027/4885RAB9A 2839/4885
US-20180044472-A1 PRODUCTION METHOD FOR POLY(AMINO ACID) PGA5, ENPEP, PARG METAP2 866/4885NPC1 4601/4885RAB9A 2457/4885
US-20200231532-A1 Supported Metal Catalysts SOD1, HNMT, SOD3 METAP2 405/4885NPC1 3027/4885RAB9A 2839/4885
US-10336864-B2 Production method for poly(amino acid) PGA5, ENPEP, PARG METAP2 866/4885NPC1 4601/4885RAB9A 2457/4885
US-20180099923-A1 Supported Metal Catalysts SOD1, HNMT, SOD3 METAP2 405/4885NPC1 3027/4885RAB9A 2839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.